Brain Tumor, Pediatric
22
7
8
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.5%
1 terminated out of 22 trials
87.5%
+1.0% vs benchmark
5%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (22)
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours
Measuring Brain Changes Following Cognitive Intervention in Pediatric Patients With Brain Tumors
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention
B7-H3.CD28Z.CART in CNS Neoplasms
Components of Social Functioning in Survivors of Pediatric Brain Tumors
Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
Social Emotional Development in Young Children With Cancer
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
GD2-CAR T Cells for Pediatric Brain Tumours
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
RE-irradiation of Diffuse MIdline Glioma paTients
Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing
Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients